Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.60 |
| ▸ | ATM | Q13315 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.53 |
| ▸ | CA2 | P00918 | 3/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.47 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.47 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.47 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | MMP8 | P22894 | 1/20 | 0.41 |
| ▸ | MMP14 | P50281 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL818398 | 1.00 | TSHR (0.71) | TSHRCYP3A4TDP1ATMALDH1A1 | |
| SCHEMBL226708 | 0.95 | TSHR (0.77) | TSHRCYP3A4TDP1ATMALDH1A1 | |
| SCHEMBL87501 | 0.95 | TSHR (0.77) | TSHRCYP3A4TDP1ATMALDH1A1 | |
| SCHEMBL423544 | 0.95 | TSHR (0.77) | TSHRCYP3A4TDP1ATMALDH1A1 | |
| SCHEMBL17433696 | 0.94 | TSHR (0.63) | TSHRCYP3A4TDP1ATMALDH1A1 | |
| SCHEMBL17433695 | 0.94 | TSHR (0.63) | TSHRCYP3A4TDP1ATMALDH1A1 | |
| Butane SCHEMBL10783052 | 0.93 | TSHR (0.75) | TSHRCYP3A4TDP1ATMALDH1A1 | |
| SCHEMBL13003694 | 0.92 | TSHR (0.61) | TSHRCYP3A4TDP1ATMALDH1A1 | |
| SCHEMBL19529571 | 0.91 | TSHR (0.73) | TSHRCYP3A4TDP1ATMALDH1A1 | |
| SCHEMBL29288070 | 0.90 | TSHR (0.71) | TSHRCYP3A4TDP1ATMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426639-B2 | Preparation of trans, trans muconic acid and trans, trans muconates | Amyris, Inc. (US) | 2013-04-23 | — | — | US | disclosed |
| US-8426639-B2 | Preparation of trans, trans muconic acid and trans, trans muconates | Amyris, Inc. (US) | 2013-04-23 | — | — | US | disclosed |
| US-8415496-B2 | Biobased polyesters | Amyris, Inc. | 2013-04-09 | — | — | US | disclosed |
| US-8415496-B2 | Biobased polyesters | Amyris, Inc. | 2013-04-09 | — | — | US | disclosed |
| US-8367858-B2 | Terephthalic and trimellitic based acids and carboxylate derivatives thereof | Amyris, Inc. (US) | 2013-02-05 | — | — | US | disclosed |
| US-8367858-B2 | Terephthalic and trimellitic based acids and carboxylate derivatives thereof | Amyris, Inc. (US) | 2013-02-05 | — | — | US | disclosed |
| US-8367859-B2 | Cyclohexane 1,4 carboxylates | Amyris, Inc. (US) | 2013-02-05 | — | — | US | disclosed |
| US-8367859-B2 | Cyclohexane 1,4 carboxylates | Amyris, Inc. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20110288310-A1 | CYCLOHEXANE 1,4 CARBOXYLATES | DRATHS CORPORATION (US) | 2011-11-24 | — | — | US | disclosed |
| US-20110288310-A1 | CYCLOHEXANE 1,4 CARBOXYLATES | DRATHS CORPORATION (US) | 2011-11-24 | — | — | US | disclosed |
| US-20110288263-A1 | BIOBASED POLYESTERS | DRATHS CORPORATION (US) | 2011-11-24 | — | — | US | disclosed |
| US-20110288263-A1 | BIOBASED POLYESTERS | DRATHS CORPORATION (US) | 2011-11-24 | — | — | US | disclosed |
| US-20110288311-A1 | NOVEL TEREPHTHALIC AND TRIMELLITIC BASED ACIDS AND CARBOXYLATE DERIVATIVES THEREOF | DRATHS CORPORATION (US) | 2011-11-24 | — | — | US | disclosed |
| US-20110288311-A1 | NOVEL TEREPHTHALIC AND TRIMELLITIC BASED ACIDS AND CARBOXYLATE DERIVATIVES THEREOF | DRATHS CORPORATION (US) | 2011-11-24 | — | — | US | disclosed |
| US-20110282078-A1 | CYCLOHEXENE 1,4 -CARBOXYLATES | DRATHS CORPORATION (US) | 2011-11-17 | — | — | US | disclosed |
| WO-2010148081-A2 | NOVEL TEREPHTHALIC AND TRIMELLITIC BASED ACIDS AND CARBOXYLATE DERIVATIVES THEREOF | DRATHS CORPORATION (US) | 2010-12-23 | — | — | WO | disclosed |
| WO-2010148063-A2 | CYCLOHEXENE 1,4-CARBOXYLATES | DRATHS CORPORATION (US) | 2010-12-23 | — | — | WO | disclosed |
| WO-2010148080-A2 | CYCLOHEXANE 1,4 CARBOXYLATES | DRATHS CORPORATION (US) | 2010-12-23 | — | — | WO | disclosed |
| US-20100314243-A1 | PREPARATION OF TRANS,TRANS MUCONIC ACID AND TRANS,TRANS MUCONATES | DRATHS CORPORATION (US) | 2010-12-16 | — | — | US | disclosed |
| US-20100314243-A1 | PREPARATION OF TRANS,TRANS MUCONIC ACID AND TRANS,TRANS MUCONATES | DRATHS CORPORATION (US) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288310-A1 | CYCLOHEXANE 1,4 CARBOXYLATES | CNR2, CBR1, CCR4 | TSHR 4873/4885CYP3A4 19/4885TDP1 2258/4885 |
| US-20110282078-A1 | CYCLOHEXENE 1,4 -CARBOXYLATES | CBR1, MCM4, CCR4 | TSHR 4840/4885CYP3A4 20/4885TDP1 2649/4885 |
| US-20110288311-A1 | NOVEL TEREPHTHALIC AND TRIMELLITIC BASED ACIDS AND CARBOXYLATE DERIVATIVES THEREOF | TRIM4, DDT, PICALM | TSHR 4009/4885CYP3A4 643/4885TDP1 1287/4885 |
| US-20100314243-A1 | PREPARATION OF TRANS,TRANS MUCONIC ACID AND TRANS,TRANS MUCONATES | MUC1, FUT6, ST6GAL1 | TSHR 762/4885CYP3A4 1105/4885TDP1 4522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.